We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more here.Close Me
On June 12, the U.S. Food and Drug Administration (FDA)
published two new guidance documents that address how companies can
share off-label information with insurers and healthcare
professionals about drugs and medical devices, as well as
information for uses that haven't yet been approved.
One guidance, "Drug and Device Manufacturer Communications With
Payors, Formulary Committees, and Similar Entities –
Questions and Answers," addresses how drug and medical
device companies can share economic and other information about
drugs and medical devices with insurance companies and other
payors. The other, "Medical Product Communications That Are Consistent
With the FDA-Required Labeling – Questions and
Answers," addresses how companies can communicate to
healthcare professionals and others information that is not
contained in a product's labeling, but is still consistent with
the labeling. This information may include data from post-market
studies and surveillance of a product's approved uses;
additional information from the pre-market studies that were used
to support approval of the product, including what uses haven't
yet been approved by the FDA; and scientific studies, including
studies comparing the safety and efficacy of one drug to
another.
The past three month of FDA guidance documents can be
found on the FDA's website.
For more articles and regular updates on legislative
changes, regulatory developments and other news of interest to
businesses, professionals and investors in the healthcare industry,
please subscribe to Day Pitney's mailing
lists.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
A new wave of change is poised to disrupt the way health care is delivered in the United States. This time around, the disruption is coming not from lawmakers or the president ...
The myriad—and conflicting—state, federal and international laws governing the burgeoning marijuana industry have created a complicated legal landscape for financial institutions.
U.S. Attorney's Offices ("USAOs") across the country are issuing warning letters to physicians and other prescribers (collectively, "Prescribers") cautioning them about their opioid prescribing
As 2019 is underway and the government is back up and running, we have summarized for you key developments from 2018 and projections for 2019 on issues that we have been monitoring closely in the cosmetics and...
Welcome to Foley's new health care MarketTrends newsletter. Each edition, we will focus on a different aspect of health care and highlight key trends in the industry.